Health Economics and Outcomes Research (HEOR)
- Evidence Planning & Study Design
- Conceptual Models
- Literature Synthesis & Meta-Analysis
- Data Sourcing, Analysis & Interpretation
- Economic Modeling, Cost Effectiveness Analysis & Budget Impact Analysis
- Web-Based Graphical Model User Interfaces
- Patient-Reported Outcomes & Utilities
- Market Access & Reimbursement
- Payer Research and Engagement
- Value Dossiers
- Peer-Reviewed Publications & Communications
- Medical device total cost of ownership (TCO) analysis
- Real-world data analysis using large datasets, including Truven, Pharmetrics, Medicare claims data, etc.
- Support to Value Analysis Teams (VAT) & Value Analysis Committees (VACs) for hospitals & health systems
- Hospital Value Analysis (HVA) of medical devices
- Clinical research monitoring and study coordination
BUSINESS ANALYTICS, LITIGATION SUPPORT & POLICY ANALYSIS
- Healthcare Management Consulting
- Data Analysis & Statistics
- Market Research
- Market Development & Expansion
- Investor Research & Analysis
- Antitrust Analysis
- Trademark infringement
- Reputational harm
- Contractual Disputes & Payer-Provider Disputes
- Review & Analysis of Medical Claims & Bills
- Reasonable Value of Medical Losses
- Policy Research
- Cost-Benefit Analysis & Cost-Impact Analysis
- Data Analytics & Simulation Modelling
- International Health
Read more:
Spotlight
- The Value of Biopharmaceutical Innovation in the U.S.
- New date- Tuesday, May 9th. AHE Presents: Symposium on Emerging Trends in U.S. Health Economic Evaluation: A Closer Look at the Role of Cost Effectiveness in U.S. Market Access, Tuesday May 9th in Morristown, NJ
- CEO John Schneider will be speaking at Research!America’s Medical Innovation 101 February briefing on Capitol Hill with Dr. Keith R. Yamamoto, Director of Precision Medicine at the University of California San Francisco, Dr. Joe V. Selby, Executive Director at PCORI, and others.
- Will an Unravelling of the Affordable Care Act Result in Meaningful Organizational Changes in U.S. Medical Care? Implications for Economic Evaluation of Drugs & Devices
- The Evolving Landscape of U.S. Payer Coverage Decisions: The Role of Health Economics and Outcomes Research
- Avalon Health Economics will be attending ISPOR Vienna, October 29th-November 2nd. John Schneider & Andrew Briggs will be teaching the Economics of Diagnostics Introduction Course on Sunday afternoon (1:00pm-5:00pm). Come say hi or sign up for the course! Let us know if you would like to schedule a time to meet in Vienna.
- Analysis of Dental and Vision Plan Non-Covered Services and Materials Mandates and the Projected Role of H.R. 3323 in the Vision and Dental Markets
- Medical Device Economics and the Health System Purchaser in the Era of Novel Payment Mechanisms
- Value-Based Payment for Oncology Services
- Why Medical Device Companies Need to Develop Economic Evidence in the U.S.
- Avalon CEO John Schneider presented at BMO Capital Markets' "The Year Ahead in Healthcare: Products, Payment and Politics" on December 15, 2015
- Philipp Schuetz joins Avalon Health Economics as a Clinical Director
- CEO John Schneider presents at Barclays HealthCare Symposium
- Reference Pricing for in vivo and in vitro Diagnostic Tests
'